Scientists Beamed Light Right Through a Man's Head For The First Time
Currently the best portable, low-cost method for monitoring the brain is functional near-infrared spectroscopy (fNIRS). Unfortunately, this can only penetrate a few centimeters down, meaning bigger, bulkier MRI machines are needed to probe deeper layers of the brain.
A new method, developed by a team from the University of Glasgow in Scotland, expands the sensitivity of fNIRS to shine light all the way through the complex combinations of bone, neurons, and tissue that make up our heads.
Doing so required a few tweaks: the researchers increased the strength of the near-infrared laser (within safe boundaries, of course), while also putting in place a more comprehensive collection setup.
Even with these adjustments, only a small trickle of photons made it from one side of the head to the other during experiments. However, it's a promising start for portable imaging methods that go deeper, giving us crucial insight into what's happening inside our skulls without opening them up.
"These findings uncover the potential to extend non-invasive light based on brain imaging technologies to the tomography of critical biomarkers deep in the adult human head," write the researchers in their published paper.
There are quite a number of caveats to mention here. The process was only successful with one out of eight study participants: a man with fair skin and no hair on his head. It needs a very specific setup, and an extended scanning time – around 30 minutes.
Those limitations are all acknowledged by the researchers, but they sacrificed certain variables (such as speed) to try and prove that it was possible to get light all the way through a human head via fNIRS – and they succeeded.
Computer models based on detailed 3D head scans were used to predict the movement of photons through the skull. These matched up closely with the actual light collected, adding further credibility to the results.
What's more, the research also found that light didn't scatter at random through the head, but rather followed preferred paths – including through parts that were more transparent, like those filled with cerebrospinal fluid. That knowledge could help brain scans be better targeted in the future.
"Different source positions on the head can then selectively isolate and probe deep regions of the brain," write the researchers.
The advantages of fNIRS are that it's a relatively inexpensive and compact technology. Imagine scans for strokes, brain injuries, and tumors that are more accessible for a wider range of people.
As future imaging devices are developed, this research should prove useful for techniques that go deeper into the brain – even if it might be a while before we can get light through the entire head in a timeframe that's practically useful.
We know that brain scans have tremendous value in everything from understanding adolescence in youngsters to treating disease towards the end of our lives, so there's a huge amount of potential here.
"Optical modalities for noninvasive imaging of the human brain hold promise to fill the technology gap between cheap and portable devices such as electroencephalography (EEG) and expensive high-resolution instruments such as functional magnetic resonance imaging (fMRI)," write the researchers.
The research has been published in Neurophotonics.
The Sad Case of The World's Youngest-Ever Alzheimer's Diagnosis
Compound That Turns People Yellow Could Protect Against Malaria
Scientists May Have Finally Figured Out How Bats Avoid Cancer
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
27 minutes ago
- Yahoo
Three more species of giraffe than previously thought, scientists say
Giraffes are one of the world's most distinct and well-loved creatures, always thought to be one species. But now scientists at the International Union for Conservation of Nature say we can welcome three more species of the world's tallest mammal. It's not the first time researchers have suggested there are four species of these giants strolling on our planet, but the latest assessment puts an official stamp on it. How did scientists work it out? And what does it mean for the future of the animal? Scientists compared the skull size and head shape of different giraffes and concluded there was enough genetic diversity for four groups to be considered as different species. The researchers looked at natural features across Africa such as deserts, rivers and valleys that could have separated animals in the past, meaning they evolved separately from each other. Say hello to the Southern giraffe, one of the newly-recognised species. This giraffe lives in South Africa, Angola, southern Botswana, Namibia, southern Zimbabwe, Zambia, and southwestern Mozambique. Two rivers (the Kunene and Zambezi) and rainforests in the Congo Basin probably separated the animals from overlapping with other giraffes. The second new species is the Reticulated giraffe. This giraffe lives in the open savannas and wooded grasslands of Kenya, Somalia, and Ethiopia. Scientists think the Tana river, Ethiopia's mountains and towns separated this animal from other giraffes in the north of the region. It is also a migrating animal, which means it may have passed by other giraffes when it could have cross-bred. The third species we can officially recognise is the Northern giraffe. This animal lives in western Ethiopia, central and western Kenya, eastern South Sudan and Uganda. Scientists say the Nile River and Lake Victoria, as well as its migration pattern, separated this giraffe from others. The fourth and final species is the beautiful Masai giraffe, with its distinctive leaf-pattern hide. It lives in Kenya, Tanzania and Uganda, separated from the Northern giraffe by Lake Victoria and the Nile River. Although its pattern makes it seem like it could be a marker of being a separate species, the scientists say that the hides vary even within one population of giraffes and as the animals age. The International Union for Conservation of Nature (IUCN) says that identifying genetic difference is "vital" for conservation and managing giraffe populations. "The more precisely we understand giraffe taxonomy, the better equipped we are to assess their status and implement effective conservation strategies," said co-author of the report Michael Brown of the IUCN. As a single species, the giraffe was classed as vulnerable to extinction, although some of the sub-species were increasing in numbers. The IUCN will now re-assess the vulnerability of the four new species and their sub-species and says it hopes to better protect the majestic animals with the new information.
Medscape
29 minutes ago
- Medscape
New First-Line Option for Advanced Bladder Cancer
The National Institute for Health and Care Excellence (NICE) has recommended the combination of enfortumab vedotin (Padcev, Astellas) with pembrolizumab (Keytruda, MSD) as a first-line option for adults with unresectable or metastatic urothelial cancer who are eligible for platinum-based chemotherapy. More than 1200 people in England are expected to benefit each year. Clinical experts described the combination therapy as a "step change" in bladder cancer management. Until now, treatment options for this patient group have seen little meaningful progress since the 1980s. Enfortumab vedotin is an antibody-drug conjugate consisting of an antibody targeting Nectin-4, a protein highly expressed in urothelial carcinoma cells. After binding, it causes the cells to release monomethyl auristatin E, resulting in cell death. Pembrolizumab, its combination partner, is a PD-1 inhibitor. High Disease Burden Urothelial cancer accounts for around 90% of bladder cancers, affecting more than 18,000 people annually in England. Prognosis is poor, with only 10% of patients with stage 4 disease surviving for 5 years or more. Current standard treatments include platinum-based chemotherapy ( cisplatin or carboplatin with gemcitabine), followed by avelumab maintenance therapy if the cancer has not progressed. However, only about 12% of patients see improvement with chemotherapy, underscoring the need for better options. Patient experts described living with metastatic urothelial cancer as "intensely challenging and emotionally exhausting', affecting work, travel, and physical activity. Action Bladder Cancer UK called the announcement a 'very welcome, and significant, step forward for this hard-to-treat cancer'. Clinical Evidence The recommendation in final draft guidance was supported by results from the phase 3 EV-302 trial, which enrolled 886 adults with untreated, unresectable, locally advanced, or metastatic urothelial cancer. Participants were randomly assigned in a 1:1 ratio to receive either enfortumab vedotin–pembrolizumab or standard chemotherapy. Enfortumab vedotin–pembrolizumab nearly doubled the median time to disease progression or death to 12.5 months, compared with 6.3 months for chemotherapy. Median overall survival was also improved, at 33.8 months versus 15.9 months with chemotherapy. Helen Knight, director of medicines evaluation at NICE, said the drug combination is 'highly promising and effective,' adding that these clinical trial results highlight the 'tremendous difference' it could make to the length and quality of people's lives. Cost and NHS Access Enfortumab vedotin is listed at £578 per 20 mg vial or £867 per 30 mg vial. Pembrolizumab costs £2630 per 100 mg vial, excluding VAT. The drugs will be supplied through confidential commercial arrangements with the NHS. NICE's appraisal committee applied a severity modifier, reflecting the high disease burden, and concluded that the therapy met acceptable cost-effectiveness thresholds. The treatment will be available immediately across the NHS in England, with funding required within 90 days of final publication of the guidance.
Medscape
an hour ago
- Medscape
Safety Watchdog Flags Ongoing Maternity Risks
The Health Services Safety Investigations Body (HSSIB) has released a preliminary report on maternity and neonatal safety in England. The exploratory review, carried out in spring 2025, highlighted concerns across the entire maternity and neonatal care pathway despite years of initiatives aimed at improvement. The review comes after a series of high-profile scandals, including at Shrewsbury and Telford Hospital NHS Trust and Nottingham University Hospitals NHS Trust. The Shrewsbury inquiry, led by senior midwife Donna Ockenden, found that approximately 201 babies and nine mothers might have survived if they had received better care. The Nottingham review — also led by Ockenden — remains ongoing. Safety Concerns and Baby Deaths The HSSIB's latest report indicates that safety concerns persist. Between October 2023 and June 2025, the board received 35 reports of safety concerns in maternity or neonatal services. These accounted for about 10% of all safety concerns received during that period. All cases involved "very serious harm", including 10 baby deaths. Sixteen incidents occurred during labour, and 12 during the neonatal period. Most reports came from women or family members, although some were submitted by healthcare staff. Full Investigation Paused The board had begun a scoping exercise to assess the need for a full investigation. However, the work was paused in June after the Secretary of State for Health and Social Care announced a national investigation into maternity and neonatal services, due to report in December 2025. Health Secretary Wes Streeting said that multiple reviews into local trusts had found "similar failings in compassionate care" after maternity service failures "that should never have happened". He acknowledged "systemic" failings dating back more than 15 years and said families had been "gaslit" in their search for answers about their babies' deaths. Although pausing its work, the HSSIB published its exploratory findings to support the national investigation. These were based on the 35 recent safety reports, meetings with 17 stakeholders, and a 2021 report by its precursor organisation, the Healthcare Safety Investigation Branch. 'Compounded Harms' to Families The report identified 11 key themes. Progress had been made in maternity and neonatal outcomes, staffing levels, and governance, but disparities in care and outcomes persisted, partly due to health inequalities. The HSSIB found that maternity and neonatal systems were overly complex, with inconsistent collaboration and poor information sharing. Local governance often operated in isolation, and services struggled to identify and respond to clinical risks or to learn from the harms that happened to women and babies during pregnancy, labour, and birth. "Patients experience compounded harm due to issues within the wider healthcare system," the report concluded. It highlighted that local investigations, complaints processes, and legal proceedings such as inquests often caused additional harm. "Staff and trusts can lose sight of compassion during this process," it said. Four Areas for Further Review The HSSIB recommended four areas for potential further investigation: National structures responsible for providing direction and oversight for maternity services. Local governance and its relationship to national bodies. Standards and approaches of local investigations when things go wrong. Education, training, and professional standards for clinicians. Staff Experience Cumulative Stress The report said that maternity and neonatal staff also experienced cumulative stress and harm. It raised concerns about the standards set in undergraduate and postgraduate education, and whether these could be met in practice, noting that too many recommendations were being made, with limited implementation. The HSSIB warned that multiple, high-profile maternity investigations and inquiries had eroded public confidence in maternity services. Some women were avoiding hospitals that had been the focus of national investigations, undermining recruitment and damaging staff morale. The report cited instances of midwives receiving death threats or being berated for working in 'failing' services. Stakeholders had told the HSSIB that clinicians had also become more risk-averse for fear of blame, a defensive approach that "drives the behaviour that compounds the harm women and families experience".
